Characterization of Systemic Amyloid Deposits by Mass Spectrometry

Charles L. Murphy, Shuching Wang, Teresa Williams, Deborah T. Weiss, Alan Solomon

Research output: Contribution to journalReview article

77 Citations (Scopus)

Abstract

The human systemic (noncerebral) amyloidoses represent a heterogeneous group of disorders characterized by the widespread deposition of proteins as fibrils in organs or tissues throughout the body. The unequivocal identification of the type of amyloid deposited is critical to the correct diagnosis and treatment of patients with these illnesses. Heretofore, this information was inferred from clinical data, ancillary laboratory tests, and results of immunohistochemical, as well as genetic, analyses. However, to establish definitively the type of amyloid present, the chemical composition of the fibrillar components must be determined. For this purpose, we have developed micro-methods, whereby this information can be obtained by tandem mass spectrometry (MS/MS) using material extracted from formalin-fixed, amyloid-containing tissue biopsy specimens or subcutaneous fat aspirates. The ability to identify precisely the protein nature of the pathologic deposits has diagnostic, therapeutic, and prognostic implications for patients with amyloid-associated disease.

Original languageEnglish (US)
Pages (from-to)48-62
Number of pages15
JournalMethods in Enzymology
Volume412
DOIs
StatePublished - Oct 17 2006

Fingerprint

Amyloid Plaques
Amyloid
Mass spectrometry
Mass Spectrometry
Deposits
Tissue
Biopsy
Subcutaneous Fat
Amyloidosis
Tandem Mass Spectrometry
Formaldehyde
Proteins
Fats
Therapeutics
Chemical analysis

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology

Cite this

Characterization of Systemic Amyloid Deposits by Mass Spectrometry. / Murphy, Charles L.; Wang, Shuching; Williams, Teresa; Weiss, Deborah T.; Solomon, Alan.

In: Methods in Enzymology, Vol. 412, 17.10.2006, p. 48-62.

Research output: Contribution to journalReview article

Murphy, Charles L. ; Wang, Shuching ; Williams, Teresa ; Weiss, Deborah T. ; Solomon, Alan. / Characterization of Systemic Amyloid Deposits by Mass Spectrometry. In: Methods in Enzymology. 2006 ; Vol. 412. pp. 48-62.
@article{d8d2b51a86194bfdb13f68bce2123f81,
title = "Characterization of Systemic Amyloid Deposits by Mass Spectrometry",
abstract = "The human systemic (noncerebral) amyloidoses represent a heterogeneous group of disorders characterized by the widespread deposition of proteins as fibrils in organs or tissues throughout the body. The unequivocal identification of the type of amyloid deposited is critical to the correct diagnosis and treatment of patients with these illnesses. Heretofore, this information was inferred from clinical data, ancillary laboratory tests, and results of immunohistochemical, as well as genetic, analyses. However, to establish definitively the type of amyloid present, the chemical composition of the fibrillar components must be determined. For this purpose, we have developed micro-methods, whereby this information can be obtained by tandem mass spectrometry (MS/MS) using material extracted from formalin-fixed, amyloid-containing tissue biopsy specimens or subcutaneous fat aspirates. The ability to identify precisely the protein nature of the pathologic deposits has diagnostic, therapeutic, and prognostic implications for patients with amyloid-associated disease.",
author = "Murphy, {Charles L.} and Shuching Wang and Teresa Williams and Weiss, {Deborah T.} and Alan Solomon",
year = "2006",
month = "10",
day = "17",
doi = "10.1016/S0076-6879(06)12004-2",
language = "English (US)",
volume = "412",
pages = "48--62",
journal = "Methods in Enzymology",
issn = "0076-6879",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Characterization of Systemic Amyloid Deposits by Mass Spectrometry

AU - Murphy, Charles L.

AU - Wang, Shuching

AU - Williams, Teresa

AU - Weiss, Deborah T.

AU - Solomon, Alan

PY - 2006/10/17

Y1 - 2006/10/17

N2 - The human systemic (noncerebral) amyloidoses represent a heterogeneous group of disorders characterized by the widespread deposition of proteins as fibrils in organs or tissues throughout the body. The unequivocal identification of the type of amyloid deposited is critical to the correct diagnosis and treatment of patients with these illnesses. Heretofore, this information was inferred from clinical data, ancillary laboratory tests, and results of immunohistochemical, as well as genetic, analyses. However, to establish definitively the type of amyloid present, the chemical composition of the fibrillar components must be determined. For this purpose, we have developed micro-methods, whereby this information can be obtained by tandem mass spectrometry (MS/MS) using material extracted from formalin-fixed, amyloid-containing tissue biopsy specimens or subcutaneous fat aspirates. The ability to identify precisely the protein nature of the pathologic deposits has diagnostic, therapeutic, and prognostic implications for patients with amyloid-associated disease.

AB - The human systemic (noncerebral) amyloidoses represent a heterogeneous group of disorders characterized by the widespread deposition of proteins as fibrils in organs or tissues throughout the body. The unequivocal identification of the type of amyloid deposited is critical to the correct diagnosis and treatment of patients with these illnesses. Heretofore, this information was inferred from clinical data, ancillary laboratory tests, and results of immunohistochemical, as well as genetic, analyses. However, to establish definitively the type of amyloid present, the chemical composition of the fibrillar components must be determined. For this purpose, we have developed micro-methods, whereby this information can be obtained by tandem mass spectrometry (MS/MS) using material extracted from formalin-fixed, amyloid-containing tissue biopsy specimens or subcutaneous fat aspirates. The ability to identify precisely the protein nature of the pathologic deposits has diagnostic, therapeutic, and prognostic implications for patients with amyloid-associated disease.

UR - http://www.scopus.com/inward/record.url?scp=33745934794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745934794&partnerID=8YFLogxK

U2 - 10.1016/S0076-6879(06)12004-2

DO - 10.1016/S0076-6879(06)12004-2

M3 - Review article

VL - 412

SP - 48

EP - 62

JO - Methods in Enzymology

JF - Methods in Enzymology

SN - 0076-6879

ER -